Mumbai, India – As Indian equity markets navigate geopolitical tensions, specific pharmaceutical stocks are drawing attention from traders. Jigar S Patel, Senior Technical Research Analyst at Anand Rathi Share and Stock Brokers, has offered key technical levels and trading strategies for Glenmark Pharmaceuticals Ltd, Wockhardt, and Aurobindo Pharma Ltd.
Wockhardt: Profit Booking Advised Amid Strong Rally
Wockhardt Ltd. has experienced a significant upward trend, trading well above its 20-day and 50-day exponential moving averages (DEMA), signaling an extended price structure. This deviation from key moving averages often increases the likelihood of a mean reversion. Momentum indicators, including MACD and DMI, are also in overbought territory, suggesting potential vulnerability to profit booking or consolidation.
Investors may consider utilizing any pullback or bounce to book partial profits. Immediate support for Wockhardt is identified near Rs 2,100, with resistance around Rs 2,420.
Glenmark Pharmaceuticals: Range-Bound with Resistance
Glenmark Pharma recently encountered strong resistance near its yearly pivot level of Rs 2,400, a point that has historically acted as a significant hurdle. The formation of multiple tops at this level indicates a lack of sustained buying conviction at higher prices, raising the possibility of further consolidation or corrective action.
The stock's short-term price structure remains cautious. Investors might consider booking profits on any meaningful bounce. Immediate support for Glenmark is placed near Rs 2,100, while resistance is anticipated around Rs 2,300. A decisive move beyond these levels would likely determine the stock's next directional trend.
Aurobindo Pharma: Buy Call After Breakout
Aurobindo Pharma is currently undergoing a healthy pullback following a decisive breakout above its yearly pivot level of Rs 1,360. From a technical standpoint, this breakout has transformed the previous resistance zone into a robust support area, making Rs 1,360 a critical level to monitor.
As long as Aurobindo Pharma sustains above this support, its broader bullish structure remains intact. The ongoing correction appears to be a retracement within an uptrend rather than a trend reversal. Analysts expect buying interest to emerge near the Rs 1,360 zone, potentially triggering a fresh upside move towards Rs 1,510 in the coming weeks. A close below Rs 1,360 could weaken this positive outlook.
Disclaimer: This article provides stock market analysis for informational purposes only and should not be construed as investment advice. Readers are encouraged to consult with a qualified financial advisor before making any investment decisions.